



NEWS RELEASE

Orion Nutraceuticals Subsidiary, Medic Oasis, Receives Building Permits to Begin Construction on Cannabis Production Facility in Quebec

Vancouver, BC, December 6, 2018 – **Orion Nutraceuticals Inc.**, (CSE: **ORI**) (the “**Company**” or “**Orion**”) a cannabis life science company, is pleased to announce their subsidiary, Medic Oasis, has received construction permits from the city of Dorval to begin building its 31,000 square-foot cannabis production facility in Quebec.

Orion is a British Columbia based company that aims to become an ACMPR Licensed Producer through its 99% owned subsidiary Medic Oasis. Medic Oasis has submitted an application to become a licensed producer and sell medical marijuana under Health Canada’s Access to Cannabis for Medical Purposes Regulations.

In July 2018, Orion entered into an 11-year commercial lease agreement for 31,688 square feet of space in the City of Dorval, Quebec, for growing, manufacturing and distributing legal cannabis. Under the lease for the Dorval Property, Orion has a right of first offer on any adjacent space which becomes available for lease. If Orion does not obtain the necessary permits to cultivate legal cannabis, it has an option to terminate the lease after the first year.

“We are extremely excited to begin renovations on our future cannabis growing facility in Dorval, Quebec,” said Jonathan Fiteni, CEO of Orion Nutraceuticals. “The province of Quebec is home to over 20% of Canada’s population yet has less than 10% of Canada’s total LP’s. Orion views this as a tremendous advantage as the government of Quebec has stated it will endeavor to fulfill its cannabis needs with product grown within the borders of Quebec.”

Once approved, Orion anticipates that the Medic Oasis project will be operational by the third quarter of 2020.

About Orion Nutraceuticals Inc.

Orion Nutraceuticals is partners with Colombian based medical cannabis corporation FCM Global. FCM supplies pharmaceutical, nutritional, wellness, and cosmetic companies in legal markets worldwide with customized medical cannabis extracts, oils, and isolates at commercial scale. Medic-Oasis, Orion’s subsidiary, has submitted its application for an ACMPR license and is currently under review with Health Canada. Build out is expected to begin in Q1 2019, with completion of the 31,000 square foot facility expected by Q3 2020. Orion Nutraceuticals Inc. aims to set a new standard in cannabis life science by producing and developing innovative products with key strategic partners in the industry. In conjunction with its professional sports strategic alliances, the company is poised to advance research and development in the plant science sector, deliver science-based products and services, and market CBD therapies to the



mainstream with proprietary brands and products. Orion shares trade in Canada on the CSE under the symbol ORI.

ON BEHALF OF THE BOARD

Jonathan Fiteni, CEO
Orion Nutraceuticals Inc.
www.orionnutra.ca

Investor Relations
Robin Linden, Director
1.604.313.2768
investors@orionnutra.ca

Keep up to date with Orion on our social media channels:

Twitter: @orionnutra
Facebook: @orionnutra
Instagram: @orionnutra
LinkedIn: @orionnutra

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.